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Abstract
Background: Poor adherence is estimated to cause 125 thousand deaths per year and is linked to 10% of all hospital stays in
the U.S. Up to one third of elderly hypertensive patients don’t have adherence, which is responsible for high proportion of
hospitalizations. Hypertension is also related to poor performance in tests that assess cognitive functions. On the other
hand, poor cognitive performance is associated with low adherence to treatment.
Objective: To assess the association between cognitive function, anxiety and psychiatric disorders with adherence to drug
treatment in patients with hypertension.
Methodology and Principal Findings: This a cohort studies with 56 adult patients with uncontrolled hypertension who
participated of all meetings of a pharmaceutical intervention in a randomized clinical trial of pharmaceutical care.
Cognitive function was measured by the Mini Mental State Examination (Mini-mental). The memory was measured by digit
and word spans, tower and church shadow test, short story test and metamemory. Anxiety and psychiatric disorders were
evaluated by the State Trace Anxiety Inventory and the Self-Report Questionnaire, respectively. The participants were
classified as adherent or non-adherent to the drug treatment, according to the identification of plasma levels of
hydrochlorothiazide. All non-adherent patients (n = 12) and 35 out 44 (79.5%) patients with adherence to treatment had at
least one memory test with an altered score (P = 0.180). Participants with an unsatisfactory score in the Mini-mental had
six-fold higher risk of non-adherence to treatment when compared to those with a normal score (RR = 5.8; CI 95%: 1.6–
20.8; P = 0.007). The scores of anxiety and psychiatric disorders were not associated with adherence to the
pharmacological treatment.
Conclusion: Cognitive deficit impairs adherence to drug therapy and should be screened as part of a program of
pharmaceutical care to improve adherence to treatment.
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Introduction
Non-adherence to medical regimens is a worldwide problem.
According to the World Health Organization (WHO), the average
rate of non-adherence in patients with chronic disease is 50% in
developed countries [1]. This may be related to poor therapeutic
results and determines the wasting of billions of dollars per year in
the United States [2]. Poor adherence is estimated to cause 125
thousand deaths per year and is linked to 10% of all hospital stays
in the U.S. [2].
Worldwide, high blood pressure is estimated to cause 7.1 million
deaths per year [3]. Hypertension, a chronic condition responsible
for high proportion of hospitalizations in Brazil [4], is related to
poor performance in tests that assess cognitive functions [5,6].
This pathology deranges memory and attention and can arouse
feelings of anxiety and depression [7], due to its diagnosis as well as
its treatment. Poor cognitive performance is associated with low
adherence to treatment [8,9], and it has been suggested that
education plays an important impact in cognitive function and
adherence [9].
Cognition is based on the successive processing of information
and the recognition of this succession [10]. Emotions, level of
consciousness and mood modulate the perception of different
stimuli to which we are exposed daily [11]. Since memory
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influences several aspects of life, and communication is the key
element to well-being and survival [11], their maladjustment can
compromise the whole performance of individuals.
The objective of this study is therefore to investigate the
hypothesis that cognitive function, anxiety and psychiatric disorders
are associated with adherence to drug therapy in patients with
uncontrolled hypertension.
Methods
This is a cohort study nested in a randomized clinical trial,
which reported the efficacy of pharmaceutical care to improve
blood pressure (BP) control [12]. The study was carried-out in the
Outpatient Hypertension Clinic of the Cardiology Division of the
Hospital de Clı́nicas de Porto Alegre (Porto Alegre, RS Brazil).
Patients had uncontrolled blood pressure. The factors studied –
cognition, memory, anxiety and psychiatric disorders – were
analyzed using specific instruments. Performance in the Mini-
Mental was the main exposure variable, since it assesses the overall
cognitive function. The outcome ‘‘adherence to treatment’’ was
determined by the presence of plasma levels of hydrochlorothia-
zide (qualitative analysis), prescribed for all patients, using high
performance liquid chromatography (HPLC ShimadzuH) coupled
to the MicromassH mass spectrometer. Blood sampling was
collected in the last consultation.
Fifty-six adult patients over 18 years of age, with uncontrolled
hypertension (BP $140/90 mmHg), were included in the analysis.
These subjects were under drug treatment with hydrochlorothi-
azide alone or in association, and were submitted to a serial of tests
of cognition, anxiety and psychiatric disorders. Patients were
followed-up for six months and the tests were applied by a
pharmacist in one of the five consultations in the follow-up.
Measurement instruments
Mini Mental State Exam – Mini-mental (MM) [13] encompasses
issues of temporal and spatial orientation, data registry, attention
and calculation, evocation of registered data and language, each
one with a specific evaluation. The maximum score is 30 points.
The cut-off point for people with 4 years or less of education is 17,
and for those with more than 4 years of education, 24 points [14].
Word span [15] assesses the immediate (WSI) and short-term
(WSST) memory and consists of the reading of a list of ten words
to the patient, who must repeat them immediately (WSI) and after
a few minutes (WSST), receiving 1 point for each correct word,
regardless of order. The cut-off point for WSI is 4 and WSST is 3.
Digit span [15] evaluates operational memory, and is a verbal
test that comprises seven numerical series. The first has 3 digits,
and one digit is added to each series until the final one, which has
9 digits. The maximum score is 14 points, and the minimum
expected is 5.
Tower and church shadow test (TCS) [16] assesses non-verbal
memory. Ten shadows are shown for 5 seconds each to the patient
and then he/she must locate each one on a sheet of paper with 44
different shadows, marking them with rings within the period of
one minute.
Short story [15] evaluates logic memory by the slow and paced
reading of a story with ten items to be remembered. The patient
must tell the story twice, once immediately after hearing it and the
other after ten minutes.
Memory Self-Assessment Scale – Metamemory [17] - evaluates
the perception that individuals have regarding their own memory.
It is comprised by ten questions that refer to the memory functions
at the moment of assessment, compared to the period before the
use of medication or the attendance to the medical service.
State Trace Anxiety Inventory (STAI) [18] evaluates anxiety
state and trace. It is divided in two parts. The first part refers to the
anxiety-state, when the patient responds according to what he/she
is feeling at the moment of the assessment. In the second part the
patient must answer according to how he/she generally feels
(anxiety-trace).
Self Report Questionnaire (SRQ) [19] evaluates the suspicion of
psychiatric disorders through questions about the life of the
patient. The Portuguese version of the SRQ 20 determines the
cut-off point for not presenting psychotic morbidity at #8 for
women and #6 for men [20].
The instruments used in this study were previously validated for
the Portuguese language and were applied by trained pharmacists.
The original study [12] and this study were approved by the
Ethics Committee of Hospital de Clı́nicas of Porto Alegre, which is
accredited by the Office of Human Research Protections as an
Institutional Review Board, and every participant signed a term of
informed consent. The duration of the trial was of six months.
Statistical analysis
Adherence to pharmaceutical treatment was categorized as
adherence or non-adherence according to the presence of
hydrochlorothiazide in the plasma. Continuous variables were
analyzed using Student’s t test, whereas categorical variables were
tested by the chi-square or Fischer’s exact tests, when appropriate.
Poisson regression analysis was employed, adjusting for robust
variables, in order to eliminate the effect of possible confounding.
Variables that presented a value of P,0.20 in the univariate
analysis of factors studied (MM e WSST) with baseline
characteristics or with outcome were entered in the multivariate
model, and the treatment in the original trial (pharmaceutical
intervention or placebo intervention) was forced in the model.
Years of education were stratified to analyze the Mini-mental
(MM) performance. Mini-mental was categorized as normal or
altered, according to the cutoffs proposed by the scale (for people
with 4 years or less of education is 17, and for those with more
than 4 years of education, 24 points). Using a convenience sample,
a power of 83% was obtained to show a difference of proportion in
categorical scores in the MM, between the individuals who
adhered to treatment and those who did not; with a probability of
error a of 5%. Analyses were carried out using the SPSS program,
version 16.0 for Windows. Sensitivity and specificity of the MM
and WSST instruments were also calculated as indicators of
adherence to treatment.
Results
Seventy-one patients participated in the randomized in the
clinical trial. Of these, 56 performed all activities and were
included in this study.
Baseline characteristics were similar between participants who
adhered and did not adhere to pharmacological treatment (Table 1).
Although there was no significant statistical difference, the absolute
proportion of patients with long lasting and uncontrolled hyper-
tension and with diabetes was higher among the non-adherent
group. More than 40% of patients in both groups presented white
coat phenomenon.
All patients who did not adhere to treatment showed at least one
altered test for immediate memory and one altered test for short-
term memory. Individual analysis of the other instruments used to
assess memory and self-perception of memory did not reveal
statistically significant differences, despite that the absolute
performance tended to be worst in non-adherent patients.
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The proportion of patients with normal score in the MM was
greater in the adherence group (81.4% vs 33%, P = 0.003). This
result could also be seen in the WSST (45.5% vs 8%, P = 0.021).
The presence of altered MM and WSST were positively associated
with non-adherence by the adjusted residue of the chi-square
analysis.
The Poisson regression analysis, adjusting for age, baseline
systolic and diastolic blood pressure and pharmacotherapeutic
intervention, is shown in Table 2. Individuals with altered Mini-
mental had six-fold greater risk of not adhering to treatment
(RR = 5.8; CI95%: 1.6–20.8, P = 0.007). For word span short-term
there was a trend for significance (RR = 6.1; CI95% 0.9–43.3,
P = 0.071).
MM showed sensitivity of 67% and specificity of 81% to predict
non-adherence, using 17 as the cut-off point for education #4
years and 24 for education .4 years. The chance of having an
altered MM was 3.6 times greater among those who did not
adhere to the pharmacological treatment. The probability of non-
adherence having normal MM was 10%.
WSST showed greater sensitivity for non-adherence than MM
(91%), and lower specificity (45%), using 3 as the cut-off point.
The probability of having an altered WSST was 1.7 times higher
among those who did not adhere to treatment, compared to those
who did adhere. The probability of non-adherence with normal
WSST was 4.8%.
When it was considered the presence of alteration in both tests,
the specificity remained similar to the MM alone, but there was
reduction in the sensitivity (25%) and in the likelihood ratio (1.0).
Considering the presence of at least one altered test, there was an
increase in the sensitivity (83%) and reduction in the specificity
(38%) and likelihood ratio (1.4).
The proportion of patients with evidence of anxiety and
psychiatric disorder in any of the several tests employed was not
statistically different between the adherence and non-adherence
groups (data not shown).
Discussion
In this study of patients with hypertension submitted to a clinical
trial of pharmaceutical care it was possible to identify an inde-
pendent association between cognitive deficit and low adherence.
Anxiety and psychiatric disorders were not associated with low
adherence.
The Mini-mental was the only test that showed an independent
association between deficit of cognition and low adherence to
treatment. This test showed also some power to detect (sensitivity
of 66%) and rule out (specificity of 81%) lack of adherence in this
context. A study conducted in Japan found a sensitivity of 75%
and a specificity of 81.5% for non-adherence with MM, using 26
as the cut-off point, for patients hospitalized with diabetes and
intolerance to glucose [21].
While some studies use MM as screening process for the
selection of patients for verification of the loss of cognitive
functions [22,23], we recommend the use of this instrument as a
determiner of the approach of the pharmacist with regard to the
patient.
Furthermore, non-adherent patients had a worse performance
in other tests, despite the absence of statistical significance. A beta
error can not be discarded. Interestingly, the issue of memory was
not similar between the tests. This may be due to the different
domains treated in each test – auditive versus visual memory,
memory of isolated symbols (as words and numbers) versus memory
of more complex context (as a short story), as well as the role of
each one of these domains in the posterior evocation of the
medical recommendations.
The digit span, WWST and short story, although evaluating
immediate and short-term memory, showed no difference between
the groups being compared, possibly because the scores obtained
Table 1. Baseline characteristics of the patients, according to the adherence to treatment, measured by plasmatic levels of
hydrochlorothiazide (mean 6 SD or n[%], when appropriate).
Characteristics Adherence (n = 44) Non-adherence (n = 12) P
Women 29 (65.9) 7 (58.3) 0.737
Age 62.569.1 58.7611.3 0.229
Years of education 6.764.4 6.6763.0 0.991
Pharmacotherapeutic follow-up 21 (47.7) 5 (41.7) 0.963
Duration of hypertension .10 years 33 (75.0) 11 (91.7) 0.427
Individuals with uncontrolled hypertension .2 years 26 (59.1) 9 (75.0) 0.503
Patients with white coat syndromea 20 (45.5) 5 (41.7) 0.999
Diabetes mellitus 16 (36.4) 6 (50.0) 0.508
No. of medications in use 6.462.3 6.463.1 0.993
No. of other illnesses 3.661.7 3.261.3 0.474
Office systolic blood pressure at baseline evaluation 165.3619.2 161.5612.1 0.518
Office diastolic blood pressure at baseline evaluation 88.5611.7 88.2611.1 0.935
aDiagnosed by Ambulatory Blood Pressure Monitoring.
doi:10.1371/journal.pone.0022925.t001
Table 2. Poison regression analysis: Mini-mental (MM) and
word span short-term (WSST) as risk factor exposition of non-
adherence.
Risk factor exposition Relative risk (RR)* CI 95% P
Altered MM 5.8 1.6–20.8 0.007
Altered WSST 6.1 0.9–43.3 0.071
*Adjusting for age, baseline systolic and diastolic blood pressure and
pharmacotherapy intervention.
doi:10.1371/journal.pone.0022925.t002
Does Cognition Affect Drug Adherence?
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e22925
were so poor (equal to or less than the minimum expected) for all
patients, regardless of the group.
In the case of the short story, patients need to recall ten points
from an entire situation, not only words, and the average scores for
immediate and short-term memory were 50% and 37%,
respectively. This test could represent a medical recommendation
situation where the patient is told a series of things he must follow.
Using this scenario, it is necessary to consider the sufficiency of
immediately, remembering only half of what was said and about
the fitness of the 1/3 law [24] regarding the memory of
information minutes after hearing it. We may have revealed the
need to use more than verbal communication tool to instruct
patients, perhaps combining this with support material whenever
necessary.
The tower and church shadow test, which evaluates immediate
and short-term visual memory, did not reveal any association with
adherence to treatment. Patient performance was good, recalling
70% of all shadows right after visualization and 60% 15 minutes
later, indicating good visual memory in this sample. Therefore, the
interventions that use this memory could probably be used to
instruct these patients.
The Memory Self-Assessment Scale was hard to apply and
probably quite complex for understanding. Therefore, this
instrument is not appropriate for assessing non-adherence.
The findings for the tests that evaluated anxiety and psychiatric
disorders did not contribute to identify reasons for non-adherence
to drug treatment. A beta error cannot be fully discarded. These
data differ from Campos’ findings, in a report that describes
symptoms of anxiety as an independent risk factor for non-
adherence [25] in patients with AIDS and the Kuhl’ findings, in a
study that describes anxiety was related to lower adherence to
several important risk-reducing recommendations after myocardi-
al infarction [26].
Pharmaceutical care has been used to improve adherence to
treatment of hypertension [12,27]. The evaluation of cognition by
the Mini-mental test and eventually the word span short-term may
help to identify patients at higher risk of low adherence to
treatment in the pharmacist consultation.
Our study has some limitations that deserve mention. In view of
the criteria of selection, which included the necessity to understand
the request for consent, diminished the probability of having
enrolled participants with relevant psychiatric disorders or high
anxiety. Despite the small sample size, however, the association of
cognitive deficit and lost of memory emerged, but the absence of
some associations may be ascribed to a beta error. On the other
side, the diagnosis of adherence by plasma levels of hydrochloro-
thiazide and the full evaluation of cognitive performance are
strengths of our investigation.
In conclusion, cognitive impairment reduces the adherence to
treatment of patients with hypertension. The screening for such
abnormalities should be considered in the pharmaceutical care of
patients, in order to minimize its influence upon the adherence to
the treatment.
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